Company news
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A (SSE:688513) news
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2025: Announcement on Voluntary Disclosure of Obtaining Drug…
Press releases — page 2
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Eperisone Hydrochloride Tablets
September 28, 2025
Announcement on Resolutions of the 8th Meeting of the 4th Board of Directors
September 23, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets
September 17, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Perampanel Tablets
September 5, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Nalfurafine Hydrochloride OD Tablets
September 1, 2025
Announcement on Progress in Completion of the Transfer of Partial Equity in the Subsidiary and Related Party Transactions
August 21, 2025
Announcement on Resolutions of the 6th Meeting of the 4th Board of Supervisors
August 18, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 1, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 1% Integer Multiple
July 28, 2025
Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
July 23, 2025
Shareholders' Inquiry Transfer Plan
July 22, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Pseudoephedrine Hydrochloride Injection
July 18, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 16, 2025
Announcement on Disciplinary Review and Supervisory Investigation of an Independent Director
July 2, 2025
Announcement on the Vesting Result in the 1st Vesting Period of Initial Grant in 2024 Restricted Stock Incentive Plan
June 27, 2025
Announcement on Resolution of the 5th Meeting of the 4th Board of Directors
June 26, 2025
Announcement on Resolution of the 4th Meeting of the 4th Board of Directors
June 11, 2025
Announcement on Voluntary Disclosure of Obtaining the 25th China Patent Excellent Award
June 8, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Axitinib Tablets
June 5, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Oxazepam Tablets
June 4, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Dacomitinib Tablets
May 27, 2025